Elke S. Perloff

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

Hyperforin content determines the magnitude of the St John's wort–cyclosporine drug interaction

Ingrid Mai, Steffen Bauer, Elke S. Perloff et al. · Clinical Pharmacology & Therapeutics · 2004 · 139 citations

ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO

Elke S. Perloff, Su Duan, Paul R. Skolnik et al. · Drug Metabolism and Disposition · 2005 · 133 citations

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies

D J Greenblatt, L VONMOLTKE, Elke S. Perloff et al. · Clinical Pharmacology & Therapeutics · 2006 · 93 citations

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC₅₀shift approach facilitates<i>k</i>_inactassay design

Elke S. Perloff, Andrew K. Mason, Shangara S. Dehal et al. · Xenobiotica · 2009 · 87 citations